IL276890B2 - Dosing regimens and methods for the treatment of multiple sclerosis using opatumumab - Google Patents
Dosing regimens and methods for the treatment of multiple sclerosis using opatumumabInfo
- Publication number
- IL276890B2 IL276890B2 IL276890A IL27689020A IL276890B2 IL 276890 B2 IL276890 B2 IL 276890B2 IL 276890 A IL276890 A IL 276890A IL 27689020 A IL27689020 A IL 27689020A IL 276890 B2 IL276890 B2 IL 276890B2
- Authority
- IL
- Israel
- Prior art keywords
- ofatumumab
- multiple sclerosis
- antibody
- treatment
- regimen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374986P | 2016-08-15 | 2016-08-15 | |
| PCT/IB2017/054909 WO2018033841A1 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL276890A IL276890A (en) | 2020-10-29 |
| IL276890B1 IL276890B1 (en) | 2023-06-01 |
| IL276890B2 true IL276890B2 (en) | 2023-10-01 |
Family
ID=59901554
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276890A IL276890B2 (en) | 2016-08-15 | 2017-08-11 | Dosing regimens and methods for the treatment of multiple sclerosis using opatumumab |
| IL313932A IL313932A (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
| IL302488A IL302488B2 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
| IL264804A IL264804B (en) | 2016-08-15 | 2019-02-12 | Regimens and methods of treating multiple sclerosis using ofatumumab |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313932A IL313932A (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
| IL302488A IL302488B2 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
| IL264804A IL264804B (en) | 2016-08-15 | 2019-02-12 | Regimens and methods of treating multiple sclerosis using ofatumumab |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US11161909B2 (enExample) |
| EP (5) | EP4252847A3 (enExample) |
| JP (2) | JP6851391B2 (enExample) |
| KR (2) | KR20200136503A (enExample) |
| CN (5) | CN120053639A (enExample) |
| AU (2) | AU2017311664C1 (enExample) |
| CA (2) | CA3101514A1 (enExample) |
| CY (1) | CY1123350T1 (enExample) |
| DE (1) | DE202017007542U1 (enExample) |
| DK (2) | DK3733712T3 (enExample) |
| ES (2) | ES2954259T3 (enExample) |
| FI (1) | FI3733712T3 (enExample) |
| HR (2) | HRP20230894T1 (enExample) |
| HU (2) | HUE051948T2 (enExample) |
| IL (4) | IL276890B2 (enExample) |
| LT (2) | LT3497132T (enExample) |
| MX (1) | MX388593B (enExample) |
| PL (2) | PL3497132T3 (enExample) |
| PT (2) | PT3497132T (enExample) |
| RS (2) | RS64541B1 (enExample) |
| RU (1) | RU2749951C2 (enExample) |
| SI (2) | SI3497132T1 (enExample) |
| TW (1) | TWI752995B (enExample) |
| WO (1) | WO2018033841A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4252847A3 (en) | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| JP7794735B2 (ja) | 2019-09-11 | 2026-01-06 | ノバルティス アーゲー | 切替え療法によるｒｍｓの治療 |
| WO2021204994A1 (en) * | 2020-04-09 | 2021-10-14 | Novartis Ag | Ofatumumab for treating ms while maintaining serum igg |
| CN117529336A (zh) * | 2021-04-14 | 2024-02-06 | 诺华股份有限公司 | 用于治疗亚洲患者的多发性硬化症的奥法木单抗 |
| WO2026099463A1 (en) | 2024-11-08 | 2026-05-15 | Novartis Ag | Glycoengineered anti-cd20 antibodies |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012096924A1 (en) * | 2011-01-10 | 2012-07-19 | Glaxo Group Limited | Novel uses |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4816401A (en) | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| MXPA02009523A (es) | 2000-03-30 | 2003-02-12 | Amgen Inc | Moleculas similares a cd20/receptor de ige y usos de las mismas. |
| IL154751A0 (en) | 2000-08-03 | 2003-10-31 | Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals | |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| AR082436A1 (es) | 2010-08-02 | 2012-12-05 | Sanofi Aventis Us Llc | Uso de teriflunomida para tratar la esclerosis multiple |
| WO2013120012A2 (en) | 2012-02-08 | 2013-08-15 | Igm Biosciences Inc. | Cdim binding proteins and uses thereof |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| CN104603124B (zh) | 2012-08-10 | 2018-04-17 | 勃林格殷格翰国际有限公司 | 用作布鲁顿酪氨酸激酶(btk)抑制剂的杂芳族化合物 |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| HK1231413A1 (zh) | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| EP3250927B1 (en) * | 2015-01-28 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Gene expression markers and treatment of multiple sclerosis |
| CN106699886A (zh) | 2015-07-13 | 2017-05-24 | 西藏海思科药业集团股份有限公司 | 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体 |
| EP4252847A3 (en) | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
| US20220389109A1 (en) | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| JP7794735B2 (ja) | 2019-09-11 | 2026-01-06 | ノバルティス アーゲー | 切替え療法によるｒｍｓの治療 |
| WO2021204994A1 (en) | 2020-04-09 | 2021-10-14 | Novartis Ag | Ofatumumab for treating ms while maintaining serum igg |
| CN117529336A (zh) | 2021-04-14 | 2024-02-06 | 诺华股份有限公司 | 用于治疗亚洲患者的多发性硬化症的奥法木单抗 |
| JP2024531314A (ja) | 2021-08-16 | 2024-08-29 | ノバルティス アーゲー | 小児ｍｓを治療するためのオファツムマブ |
-
2017
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en not_active Withdrawn
- 2017-08-11 CN CN202510270961.2A patent/CN120053639A/zh active Pending
- 2017-08-11 EP EP25225892.6A patent/EP4711008A3/en active Pending
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active Ceased
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 EP EP24166956.3A patent/EP4371611B1/en active Active
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Ceased
- 2017-08-11 CN CN202510270924.1A patent/CN120000782A/zh active Pending
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-11 IL IL313932A patent/IL313932A/en unknown
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 MX MX2019001860A patent/MX388593B/es unknown
- 2017-08-11 AU AU2017311664A patent/AU2017311664C1/en active Active
- 2017-08-11 CN CN202510270941.5A patent/CN120053638A/zh active Pending
- 2017-08-11 CN CN202510270903.XA patent/CN120037367A/zh active Pending
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en not_active Ceased
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-11 IL IL302488A patent/IL302488B2/en unknown
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112C1/en active Active
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US12570754B2/en active Active
-
2024
- 2024-03-06 US US18/597,624 patent/US12338290B2/en active Active
-
2025
- 2025-05-28 US US19/221,422 patent/US20250289902A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012096924A1 (en) * | 2011-01-10 | 2012-07-19 | Glaxo Group Limited | Novel uses |
Non-Patent Citations (4)
| Title |
|---|
| ANONYMOUS:, GENMAB ANNOUNCES PHASE III STUDIES OF OFATUMUMAB IN RELAPSING MULTIPLE, 2 June 2016 (2016-06-02) * |
| BAR-OR A ET AL:, THE MIRROR STUDY: TREATMENT PHASE RESULTS FOR A DOSE- RANGING STUDY OF OFATUMUMAB IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS, 29 April 2014 (2014-04-29) * |
| BAR-OR, AMIT, ET AL., THE MIRROR STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO INVESTIGATE THE SAFETY AND MRI EFFICACY OF SUBCUTANEOUS OFATUMUMAB IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)(S23. 006)., 8 April 2014 (2014-04-08) * |
| KURRASCH, REGINA, ET AL., SUBCUTANEOUSLY ADMINISTERED OFATUMUMAB IN RHEUMATOID ARTHRITIS: A PHASE I/II STUDY OF SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS., 1 June 2013 (2013-06-01) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12338290B2 (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
| HK40111448A (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
| HK40101642A (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
| RU2782069C2 (ru) | Схемы и способы лечения рассеянного склероза с применением офатумумаба | |
| HK40032047A (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
| HK40032047B (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
| HK40005527B (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
| HK40005527A (en) | Regimens and methods of treating multiple sclerosis using ofatumumab |